Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting Survivin and XIAP

Journal of Pineal Research

Volumn 55, Issue 2, 2013, Pages 174-183

  Fan, Lulu ^a   Sun, Guoping ^a   Ma, Tai ^a   Zhong, Fei ^a   Wei, Wei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; COX 2; Hepatocellular carcinoma; Inhibitor of apoptosis proteins; Melatonin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLOOXYGENASE 2; MELATONIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS; ANTIOXIDANT; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; XIAP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEPG2; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; TISSUE MICROARRAY; ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG SCREENING; FEMALE; HEPG2 CELL LINE; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; DRUG EVALUATION, PRECLINICAL; FEMALE; HEP G2 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MALE; MELATONIN; MIDDLE AGED; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; YOUNG ADULT;

EID: 84885178908     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12060     Document Type: Article

References (40)

1. GIMENEZ-BONAFE P, TORTOSA A, PEREZ-TOMAS R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 2009; 9:320-340.
2. MOR G, MONTAGNA MK, ALVERO AB. Modulation of apoptosis to reverse chemoresistance. Methods Mol Biol 2008; 414:1-12.
3. AUGELLO C, CARUSO L, MAGGIONI M et al. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 2009; 9:125.
4. STRAUB CS. Targeting IAPs as an approach to anti-cancer therapy. Curr Top Med Chem 2011; 11:291-316.
5. GYRD-HANSEN M, MEIER P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10:561-574.
6. MANNHOLD R, FULDA S, CAROSATI E. IAP antagonists: promising candidates for cancer therapy. Drug Discov Today 2010; 15:210-219.
7. REITER RJ, TAN DX, FUENTES-BROTO L. Melatonin: a multitasking molecule. Prog Brain Res 2010; 181:127-151.
8. MOTILVA V, GARCIA-MAURINO S, TALERO E et al. New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin. J Pineal Res 2011; 51:44-60.
9. GALANO A, TAN DX, REITER RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51:1-16.
10. REITER RJ, MELCHIORRI D, SEWERYNEK E et al. A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res 1995; 18:1-11.
11. SANCHEZ-HIDALGO M, LEE M, DELA LASTRA CA et al. Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines. J Pineal Res 2012; 53:366-373.
12. WANG J, XIAO X, ZHANG Y et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 2012; 53:77-90.
13. KHAN Z, KHAN N, TIWARI RP et al. Biology of Cox-2: an application in cancer therapeutics. Curr Drug Targets 2011; 12:1082-1093.
14. MERIC JB, ROTTEY S, OLAUSSEN K et al. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 2006; 59:51-64.
15. FORNER A, LLOVET JM, BRUIX J. Hepatocellular carcinoma. Lancet 2012; 379:1245-1255.
16. LIVRAGHI T, MAKISALO H, LINE PD. Treatment options in hepatocellular carcinoma today. Scand J Surg 2011; 100:22-29.
17. SCHATTENBERG JM, SCHUCHMANN M, GALLE PR. Cell death and hepatocarcinogenesis: dysregulation of apoptosis signaling pathways. J Gastroenterol Hepatol 2011; 26(Suppl 1):213-219.
18. MUNTANE J. Targeting cell death and survival receptors in hepatocellular carcinoma. Anticancer Agents Med Chem 2011; 11:576-584.
19. NDUBAKU C, COHEN F, VARFOLOMEEV E et al. Targeting inhibitor of apoptosis proteins for therapeutic intervention. Future Med Chem 2009; 1:1509-1525.
20. CHEN L, LIANG L, YAN X et al. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer. Int J Gynecol Cancer 2013; 23:256-263.
21. ROSATO A, MENIN C, BOLDRIN D et al. Survivin expression impacts prognostically on NSCLC but not SCLC. Lung Cancer 2013; 79:180-186.
22. HOLT SV, BROOKES KE, DIVE C et al. Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents. Oncol Rep 2011; 25:1177-1181.
23. KHAN Z, TIWARI RP, KHAN N et al. Induction of apoptosis and sensitization of head and neck squamous carcinoma cells to Cisplatin by targeting survivin gene expression. Curr Gene Ther 2012; 12:444-453.
24. BONNEFONT-ROUSSELOT D, COLLIN F, JORE D et al. Reaction mechanism of melatonin oxidation by reactive oxygen species in vitro. J Pineal Res 2011; 50:328-335.
25. TAN DX, CHEN LD, POEGGELER B et al. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60
26. LALIENA A, SANMIGUEL B, CRESPO I et al. Melatonin attenuates inflammation and promotes regeneration in rabbits with fulminant hepatitis of viral origin. J Pineal Res 2012; 53:270-278.
27. LIM HD, KIM YS, KO SH et al. Cytoprotective and antiinflammatory effects of melatonin in hydrogen peroxide-stimulated CHON-001 human chondrocyte cell line and rabbit model of osteoarthritis via the SIRT1 pathway. J Pineal Res 2012; 53:225-237.
28. GONZALEZ A, DEL CASTILLO-VAQUERO A, MIRO-MORAN A et al. Melatonin reduces pancreatic tumor cell viability by altering mitochondrial physiology. J Pineal Res 2011; 50: 250-260.
29. GARCIA-NAVARRO A, GONZALEZ-PUGA C, ESCAMES G et al. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007; 43:195-205.
30. JUNG-HYNES B, REITER RJ, AHMAD N. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res 2010; 48:9-19.
31. UM HJ, PARK JW, KWON TK. Melatonin sensitizes Caki renal cancer cells to kahweol-induced apoptosis through CHOPmediated up-regulation of PUMA. J Pineal Res 2011; 50: 359-366.
32. ZHA L, FAN L, SUN G et al. Melatonin sensitizes human hepatoma cells to endoplasmic reticulum stress-induced apoptosis. J Pineal Res 2012; 52:322-331.
33. LEJA-SZPAK A, JAWOREK J, PIERZCHALSKI P et al. Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res 2010; 49:248-255.
34. GHOSH N, CHAKI R, MANDAL V et al. COX-2 as a target for cancer chemotherapy. Pharmacol Rep 2010; 62:233-244.
35. RIZZO MT. Cyclooxygenase-2 in oncogenesis. Clin Chim Acta 2011; 412:671-687.
36. MAHAJAN K, MAHAJAN NP. PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol 2012; 227:3178-3184.
37. SADEGHI N, GERBER DE. Targeting the PI3K pathway for cancer therapy. Future Med Chem 2012; 4:1153-1169.
38. LIU P, CHENG H, ROBERTS TM et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627-644.
39. UDDIN S, AHMED M, HUSSAIN A et al. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 2010; 126:382-394.
40. LIN MT, LEE RC, YANG PC et al. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2001; 276:48997-49002.